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Background: Rotaviruses are the single most important cause of severe diarrhea in young children worldwide. The
current study was conducted to assess whether colostrum containing rotavirus-specific antibodies (Gastrogard-R
®)
could protect against rotavirus infection. In addition, this illness model was used to study modulatory effects of
intervention on several immune parameters after re-infection.
Methods: BALB/c mice were treated by gavage once daily with Gastrogard-R
® from the age of 4 to 10 days, and
were inoculated with rhesus rotavirus (RRV) at 7 days of age. A secondary inoculation with epizootic-diarrhea
infant-mouse (EDIM) virus was administered at 17 days of age. Disease symptoms were scored daily and viral
shedding was measured in fecal samples during the post-inoculation periods. Rotavirus-specific IgM, IgG and IgG
subclasses in serum, T cell proliferation and rotavirus-specific delayed-type hypersensitivity (DTH) responses were
also measured.
Results: Primary inoculation with RRV induced a mild but consistent level of diarrhea during 3-4 days post-
inoculation. All mice receiving Gastrogard-R
® were 100% protected against rotavirus-induced diarrhea. Mice
receiving both RRV and EDIM inoculation had a lower faecal-viral load following EDIM inoculation then mice
receiving EDIM alone or Gastrogard-R
®. Mice receiving Gastrogard-R
® however displayed an enhanced rotavirus-
specific T-cell proliferation whereas rotavirus-specific antibody subtypes were not affected.
Conclusions: Preventing RRV-induced diarrhea by Gastrogard-R
® early in life showed a diminished protection
against EDIM re-infection, but a rotavirus-specific immune response was developed including both B cell and T cell
responses. In general, this intervention model can be used for studying clinical symptoms as well as the immune
responses required for protection against viral re-infection.
Background
Rotavirus is one of the leading causes of severe dehy-
drating diarrhea in children under the age of five and
causes the deaths of >600,000 children annually [1].
Rotaviruses, belonging to a genus of double-stranded
RNA viruses in the family Reoviridae, infect the mature
villus epithelial cells of the small intestine, often leading
to fever, vomiting, and diarrhea in children. Current
treatment is non-specific and consists mainly of oral
rehydration therapy to prevent dehydration. Two live-
attenuated vaccines have been licensed recently and
have so far proven safe and efficacious [1]. However,
previous experience with the first licensed rotavirus vac-
cine, which was withdrawn from the market a year after
introduction due to a possible correlation between vac-
cine application and the occurrence of intussusceptions
[2], has reinforced the need to develop alternative
approaches to control rotavirus disease. Fundamental to
this development is a better insight of the immune
responses related to gastrointestinal virus infections
which will help to develop improved treatment and/or
preventive regimes.
Mice provide a reliable animal model for studying the
immune responses during a primary rotavirus infection,
although the kinetics of rotavirus infections in mice dif-
fers slightly from what is observed in humans [3].
Unlike infant mice which are susceptible to symptomatic
infection with rotavirus only during the first 15 days of
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infections up to the age of five years. There are even
many reports of adult rotavirus infection, particularly in
the elderly [4]. Aside from these differences, studies of
rotavirus infection in mice can provide valuable infor-
mation on the induction of immune responses by the
virus. Sheridan et al. was one of the first to describe a
mouse model studying rotavirus-specific immunity.
Their findings indicate that (i) infection occurs in all age
groups but diarrheal disease is observed in neonatal ani-
mals only and that (ii) re-infection of adult animals is
associated with suppression of virus-specific cell-
mediated immunity [5].
Despite many years of research, the immune correlates
of protection from rotavirus infection and disease are
still not completely understood. The mouse model has
been extensively used to investigate the contribution of
different components of the immune system necessary
for protection. These studies have suggested that both
humoral- and cell-mediated immunity are important in
the resolution of ongoing rotavirus infection and in pro-
tection against subsequent re-infection [6]. In more
detail, studies have shown that B cells were essential for
long-term protection against rotavirus [7]. CD4
+ T cells
were pivotal for the development of approximately 90%
of the rotavirus-specific intestinal IgA. Their presence
seems to be critical for the establishment of protective
long-term memory responses and IgA antibody in
serum and stool samples correlates best with protection
against re-infection [8,9]. CD8
+ T cells appeared to be
involved in providing partial protection against re-infec-
tion [10,11].
The original neonatal mouse model has been developed
in order to determine the effects of an immature immune
system on responses to candidate vaccines [12]. In the
present study, this model has been modified to a sensitive
gastrointestinal viral infection and illness model in infant
mice for testing nutritional compounds for their antiviral
and/or immunomodulatory activity. Therefore, neonatal
mice were inoculated with a rhesus rotavirus strain
(RRV) at an early age for immune induction and later
challenged with epizootic-diarrhea infant-mouse (EDIM)
virus. Protection due to intervention with the nutritional
supplement Gastrogard-R
® was determined by reduction
of diarrhea and protection against later EDIM challenge,
measured by rotavirus fecal-shedding. Associations
between protection and both humoral (antibody) and cel-
lular (T cell) responses were examined.
Gastrogard-R
® is prepared from the colostrum of hyper-
immunised cows and contains high antibody titers against
four human rotavirus serotypes, as measured in a virus
neutralisation test [13]. It is used as prophylactic treatment
of ‘at risk’ children aged one month to three years to
prevent diarrhea due to rotavirus infection and the efficacy
of treatment was established in a clinical trial in children
aged 3 to 15 months [13].
The purpose of this study was to demonstrate a modi-
fied gastro-intestinal viral re-infection model for studying
the effects of nutritional intervention on clinical symp-
toms as well as the development of immune responses
and protection against subsequent viral infection.
Methods
Viruses
To obtain a large quantity of virulent epizootic-diarrhea
infant-mouse virus (EDIM), 78 neonatal mice were
inoculated at the age of 4 days with 5 μl EDIM 7.8*10
7
focus forming units/ml, a kind gift from Dr. Richard
Ward, Cincinnati Children’s Hospital Medical Center,
USA. Stool samples were collected and pooled from day
5 until day 13 and EDIM was extracted with genetron
(1,1,2-trichloro-1,2,2,-trifluoroethane, Sigma-Aldrich,
Zwijndrecht, The Netherlands). The stool preparation of
EDIM contained 400 μg rotavirus/ml as determined in
the IDEIA ELISA (Dako diagnostics, Glostrup, Den-
mark) verified against a rotavirus stock with known con-
centration of rotavirus. To determine whether EDIM
caused diarrheal disease when orally administered to
neonatal mice, 7 mice were inoculated with 5 μlE D I M
(400 μg rotavirus/ml) at the age of 7 days. At day 2 p.i.,
70% of the mice were suffering from diarrhea, rising to
100% at day 5 and declining again from day 6.
The rhesus rotavirus (RRV) strain used in this study,
also provided by Dr. Richard Ward, was grown in Afri-
can green monkey kidney MA104 cells (ECACC, Salis-
bury, UK) and concentrated by ultracentrifugation. The
titer was determined using a titration assay in MA104
cells resulting in a 50% cell culture infective dose
(CCID50)o f1×1 0
7.7. Virus stocks were UV-inactivated
o v e r n i g h ta ts h o r tw a v eU V2 5 4n m( U Vc a b i n e tC M -
10; Alltech, Breda, The Netherlands) and used for mea-
suring delayed-type hypersensitivity (DTH) responses
and T cell stimulation. Inactivation of rotavirus was
confirmed using the titration assay in MA104 cells. For
DTH responses, the EDIM and RRV stocks were diluted
100× in PBS. For use in T cell stimulation experiments,
caesium chloride gradient purified EDIM double layered
particles (provided by Dr. Richard Ward) were diluted
to 1 μg/ml and RRV was diluted to a CCID50 of 5 × 10
7.
Simian rotavirus, SA-11, (ATCC, Middlesex, UK) was
grown in MA104 cells and concentrated by ultracentri-
fugation. SA-11 contained 14 μg rotavirus/ml as deter-
mined in the IDEIA ELISA, verified against a rotavirus
stock with known concentration of rotavirus. For the
determination of rotavirus-specific antibodies in serum a
concentration of 500 ng/ml SA-11 was used.
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Pregnant female BALB/c mice were housed individually
in sterile micro-isolation cages under standard housing
conditions at the animal facility of the Dutch Vaccine
Institute with a 12 h dark and light cycle. Animal care
and use were performed in accordance with the guide-
lines of the Dutch Committee of Animal Experiments.
Weaning of suckling pups occurred at 21 days of age.
Alternatively, pups immunized and challenged prior to
weaning remained with their dams.
Study design
A total of 91 neonatal mice were cross-fostered and
divided into 4 study groups as depicted in Table 1. A
schematic design of the mouse model is shown in Figure
1. From day 4 until day 10 of age, pups of group D
received daily 20 μl PBS containing rotavirus-specific
antibodies, Gastrogard-R
®, (kindly provided by Dr. Rosie
Pereira) (1 mg/day) by oral gavage. At day 7 of age,
pups of group A, C and D were inoculated by oral
gavage with 10 μlR R V( C C I D 50 1×1 0
7.7)a n dm i c eo f
group B were inoculated with 10 μl PBS as a control.
From day 8 until day 14, diarrhea and severity of illness
was scored. From day 8 until day 27 feces were collected
daily, the feces of all animals within one group were
pooled each day. At day 16 of age, a blood sample was
taken and pooled from all animals within one group. At
d a y1 7o fa g e ,p u p so fg r o u pB ,Ca n dDw e r ei n o c u -
lated with 5 μl EDIM (400 μg rotavirus/ml) and mice of
group A were inoculated with 10 μl PBS as a control. At
d a y2 7o fa g ear o t a v i r u s - s p e c i f i cD T Hw a se l i c i t e db y
subcutaneous inoculation of UV-inactivated rotavirus in
the ear pinnea, EDIM (1 μg/ml) in the left ear and RRV
(CCID50 5×1 0
7)i nt h er i g h te a r .N o n - i n o c u l a t e dm i c e
of comparable age were also injected as a control.
Twenty four hours later, the DTH responses were deter-
mined by measuring ear thickness using a digital micro-
meter (Mitutoyo, Veenendaal, The Netherlands) prior to
collection of individual spleen and individual blood
samples.
Diarrhea and severity of illness scoring
Daily evaluation, starting 1 day after RRV inoculation,
for the presence of diarrhea (defined as having diarrheal
stool after gentle palpation of the abdomen) was per-
formed for each animal, and results were reported as
the percent of animals having diarrhea in each group.
Stool samples were collected daily, the feces of all ani-
mals within one group were pooled each day. The sever-
ity of illness was scored daily by assigning numeric
values to the color of stool where a high score indicates
severe illness (yellow = 3; yellow-brown = 2; brown =
1), degree of soiling (very soiled = 4; somewhat soiled =
1; no soiling = 0), and consistency (very liquid = 4;
liquid = 3; solid = 1) of the stool. The severity score was
calculated by dividing the total severity score by the
total number of animals on each day after RRV immuni-
zation [12].
Detection of rotavirus in feces
A commercial ELISA kit (IDEIA; Dako diagnostics) for
the detection of group A rotavirus in human fecal sam-
ples was used according to the manufacturer’sp r o t o c o l .
In short, precoated wells with rotavirus-specific polyclo-
nal antibody were sampled with a reference EDIM stock
with known concentration (300 ng/ml) which was used
as a standard, stool samples (dilutions 5×, 10×, 50× and
100×), positive and negative control supplied in the kit.
Then 100 μl rotavirus-specific polyclonal antibody-per-
oxidase labeled was added and incubated for 1 hour at
RT. Wells were washed with 350 μl wash buffer and
incubated with 100 μl of TMB substrate for 10 min. at
room temperature (RT). The reaction was stopped by
adding 100 μl of 0.46 mol/L sulfuric acid and the absor-
bance was measured at 450 nm on a microplate reader
(BioRad, Hemel Hempstead, UK). The ELISA cutoff was
the mean absorbance of the negative control at 450 nm
plus a factor of 0.1. The absorbance of the positive con-
trol should be in the range indicated at the validation
inlay in the kit. Concentration of rotavirus in the sam-
ples was expressed in ng/ml.
In vitro Concanavalin A and rotavirus-specific proliferation
of spleen cells
Spleen cells of individual mice of group A (n = 22),
group B (n = 23), group C (= 24), group D (n = 22) and
a control group of non-inoculated mice (n = 15) were
isolated by using a cell strainer 40 μm( B DF a l c o n ,
Table 1 Study design of inoculation of mice with RRV and/or EDIM and intervention
Group n (pups) RRV at day 7 of age EDIM at day 17 of age Intervention at day 4 - 10 of age
Group A 22 x - -
Group B 23 - x -
Group C 24 x x -
Group D 22 x x Gastrogard-R
®
Group A received RRV only, group B received EDIM only as controls. Groups C and D received both RRV and EDIM. Group D received daily 20 μl PBS containing
rotavirus-specific antibodies (Gastrogard-R
®) 1 mg/day.
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cells were incubated with 5 ml ice-cold lysis buffer (4.15
g ammonium chloride (Merck, Haarlem, The Nether-
lands) + 0.5 g potassium bicarbonate (Sigma-Aldrich,
Zwijdrecht, The Netherlands) + 18.6 mg EDTA (Sigma-
Aldrich) in 500 ml water, pH 7.3) and incubated for 5
minutes on ice for lysing red blood cells. After incuba-
tion, 10 ml of ice-cold culture medium, RPMI-1640
(Life Technologies, Breda, The Netherlands) + heat
inactivated 10% FBS (Perbio Science, Etten-Leur, The
Netherlands) + penicillin 50 U/ml and streptomycin 50
μg/ml (Life Technologies) + 1% sodium pyruvate (Life
Technologies) was added. The cell suspension was cen-
trifuged for 5 min. at 400 × g and 4°C (Sorvall RT7,
Thermo Fisher Scientific, Breda, The Netherlands) and
resuspended in 2 ml ice-cold culture medium. For the
Con A type IV (Sigma-Aldrich) stimulation, 2 × 10
5
cells were stimulated with 3 μg/ml Con A. For the rota-
virus-specific stimulation, 1 × 10
6 cells were stimulated
with 5 × 10
7 CCID50 UV-inactivated RRV or 1 μg/ml
UV-inactivated EDIM dl particles. Plates were incubated
at 37°C and 5% CO2. Con A proliferated cells were
pulsed after 24 hours and the rotavirus-specific prolifer-
ated cells after 5 days with 0.4 μCi/well tritium-thymi-
dine (PerkinElmer, Groningen, The Netherlands) and
incubated overnight. Cells were harvested on filter plates
(Unifilter GF-C; PerkinElmer) and radioactivity was
determined in 25 μl of scintillation cocktail (Ultima
gold; PerkinElmer) in a Wallac MicroBeta liquid scintil-
lation detector (PerkinElmer). Stimulation index was
calculated as the ratio of counts per minute for antigen-
stimulated cultures to background cultures.
Detection of serum rotavirus-specific IgM, IgG and IgG-
subclass antibodies
Serum samples were collected from mice bled from the
orbital sinus and centrifuged 10 minutes at 400 × g (Sor-
vall RT7; Thermo Fisher Scientific). Wells of a 96-well
plate (BD Falcon, Breda, The Netherlands) were coated
overnight with 100 μl 500 ng/well of simian rotavirus (SA-
11) at 4°C. As described previously, SA-11 is an efficient
EDIM antigen substitute in an ELISA [5]. Wells were
washed 4× with 200 μl PBS (Life Technologies) + 0.05%
Tween 20 (Merck) and blocked for 30 min. at 37°C with
200 μl assay buffer (PBS + 0.5% BSA (MP Biomedicals,
Eindhoven, The Netherlands) + 0.05% Tween 20). As
reference serum, the sera from pups and mothers from a
previous EDIM passage experiment that was shown to
contain antibodies to rotavirus were used. For each isotype
or subclass, a different reference serum with the highest
titer, tested in a serial dilution series starting from a 1:10
dilution, was selected and set to the arbitrary unit (AU) of
100. At day 16, individual serum samples were collected
and then pooled per group. At day 28 individual serum
samples were collected and were tested individually. Serial
dilutions in 100 μl were made of the reference serum and
individual serum samples, starting from a 1:10 dilution in
assay buffer. Wells were washed as described above and
incubated for 1 hour at 37°C with 100 μl 1:7,500 goat anti-
mouse IgM μ-chain-HRP (Sigma-Aldrich) or 1:1,000 goat
Figure 1 Schematic design of the rotavirus double infection model. At day 0 the pups were born. From day 4 until day 10 after birth pups
one group received intervention of rotavirus-specific antibodies (Gastrogard-R
®) by oral gavage. At day 7 of age pups were inoculated with RRV
by oral gavage. From day 8 on, the number of pups experiencing illness and the severity of illness was scored daily. From day 8 until the end of
the experiment, feces were collected. At day 16 a blood sample was collected and at day 17 of age pups were inoculated with EDIM by oral
gavage. At day 27 of age a rotavirus-specific DTH was elicited by subcutaneous inoculation of rotavirus in the ear pinnea, EDIM in the left ear
and RRV in the right ear. DTH responses were measured 24 hours later, prior to collection of spleen and blood samples.
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Netherlands) or 1:5,000 goat anti-mouse IgG1-HRP (AbD
Serotec, Düsseldorf, Germany) or 1:1,000 goat anti-mouse
IgG2a-HRP (AbD Serotec) or 1:1,000 goat anti-mouse
IgG2b-HRP (AbD Serotec) or 1:1,000 goat anti-mouse
IgG3-HRP (AbD Serotec) in assay buffer. Plates were
washed, 100 μl3 , 3 ’,5,5’-tetramethylbenzidine (TMB; Per-
bio Science) was added and incubated for 10 min at room
temperature. The reaction was stopped with 100 μl1 0 %
sulphuric acid (Merck) and the absorbance measured at
450 nm on a microplate reader (BioRad). Results were cal-
culated against the reference serum and expressed in AU.
Limit of detection: 0.15 AU for IgG and IgM, 2.5 AU for
I g G 1 ,0 . 6A Uf o rI g G 2 a ,0 . 1 5A Uf o rI g G 2 ba n d0 . 3A U
for IgG3.
Statistical analysis
Power calculation indicated a group size of at least 13
animals to find significant differences in diarrheal score
(detectable difference in diarrheal score = 20%, expected
CV = 15%, a =0 . 0 5 ,b = 0.20). All statistical analyses
were performed using the statistical software package
GraphPad Prism, version 4.03. A two-sample t test was
used when two groups were compared. Values of P less
than 0.05 were considered significant.
Results
Diarrhea and severity of illness score of RRV infected pups
Diarrhea and severity of illness was monitored daily dur-
ing the first RRV infection from day 8 (1 day p.i.) until
day 14 of age. Diarrhea in mice inoculated with RRV
(group A and C combined) appeared at day 9 with 63%
of the pups having symptoms of diarrhea, rising to a
maximum of 70% at day 10 and declining to zero at day
13 (Figure 2A). When the mice were supplemented with
rotavirus-specific antibodies (Gastrogard-R
®) orally
(group D) prior and during the RRV infection, no signs
of diarrhea occurred indicating a complete protection
against RRV induced diarrhea.
The severity of illness score, as depicted in Figure 2B,
was monitored daily by assigning numeric values to the
color of stool. A high score indicates severe illness,
minimum score is 2 (18.2%) and maximum score is 11
(100%). Illness in mice inoculated with RRV (group A
and C combined) appeared at day 9 with an average
severity score of 38.6%, reaching a maximum of 52.3%
at day 10 and declining after day 11. Mice supplemented
with Gastrogard-R
® orally prior and during the RRV
infection showed no signs of illness.
Viral shedding of RRV in feces
Viral shedding in the feces was detected by measuring
the amount of virus antigen shed after the RRV inocula-
tion at day 7. Rotavirus in the feces after RRV
inoculation was detectable but in low levels (between
15-130 ng/ml) during RRV infection (group A and C),
but no rotavirus was detected in the Gastrogard-R
®
group (group D) (data not shown).
Viral shedding of EDIM in feces
Viral shedding in the feces was detected by measuring
the amount of virus antigen shed after the EDIM inocula-
tion at day 17. The results of the viral shedding after the
EDIM inoculation are depicted in Figure 3. A primary
infection with RRV decreased viral shedding by 81% dur-
ing a secondary infection with EDIM (Figure 3B) com-
pared to infection with EDIM alone (Figure 3A). Similar
findings have previously been described with heterolo-
gous rotavirus infection in mice [8,12]. Intervention with
Gastrogard-R
® had 100% protected the mice against RRV
induced diarrhea, but viral shedding during the second-
ary infection with EDIM showed no significant difference
compared to the EDIM alone group (Figure 3C). How-
ever, in the EDIM group, shedding of rotavirus was mea-
sured up until day 27, whereas in the Gastrogard-R
®
group, no rotavirus was detected in the feces after day 24.
This might indicate that passive protection against a pri-
mary illness does not protect against viral shedding dur-
ing a secondary infection, though clearing of rotavirus
seemed more rapid in the Gastrogard-R
® group than in
mice inoculated with EDIM alone.
Delayed-type hypersensitivity (DTH) reaction to rotavirus
EDIM and RRV
To analyze RRV- and EDIM-specific cell-mediated immu-
nity of all study groups, a DTH response was measured by
subcutaneous injection of rotavirus in the ear pinnea, RRV
CCID50 of 2.5 × 10
7 in the right ear and EDIM 4 μg/ml in
the left ear (Figure 4). As a control, the same rotaviruses
were also administered to non-inoculated mice (n = 15) of
t h es a m ea g e .T h e r ew a sl i t t l em e a s u r a b l es w e l l i n gc o m -
pared to the control with RRV (data not shown). It has
been shown previously that a rotavirus-specific DTH
response was not elicited when neonatal mice were
infected at any time point after primary infection [5].
EDIM induced a small but significant (p = 0.01) increase
in ear swelling in the EDIM group (group B) compared to
the control, indicating the induction of specific cellular
immunity. The RRV (group A), RRV+EDIM (group C)
and Gastrogard-R
® (group D) groups were all comparable
to the control. This might indicate that mice who received
a primary infection at a young age show a DTH suppres-
sion when re-infected at an older age.
In vitro Concanavalin A and rotavirus-specific proliferation
in spleen cells
To analyze T cell responses, spleen cells from all study
groups were isolated and ex vivo restimulated with
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control, spleen cells of non-inoculated mice (n = 15) of
the same age were used. Con A induced a significant sti-
mulation of T cell proliferation with an average stimula-
tion index (Con A stimulated cells/non-stimulated cells)
of approximately 30. However, there were no differences
seen between the groups (data not shown). Incubation
of the spleen cells with EDIM showed no proliferation
(data not shown), but RRV incubation induced prolifera-
tion of T cells as shown in Figure 5. The RRV+EDIM
Figure 2 Diarrhea and illness severity score after RRV infection. Percent of pups suffering from diarrhea (A) during RRV infection of group A and C
combined (n = 46) administered at day 7 and of pups receiving rotavirus-specific antibodies (RRV infection + Gastrogard-R
®; n = 22)). Diarrhea was
monitored from day 8 until day 14. Bars represent the mean percentage of pups ± SEM per day having symptoms of diarrhea. Severity of illness score
(B) during RRV infection of group A and C combined (n = 46) administered at day 7 and of pups receiving rotavirus-specific antibodies (RRV infection
+ Gastrogard-R
®; n = 22). Severity of illness was monitored daily by assigning numeric values to the color of stool where a high score indicates severe
illness (yellow = 3; yellow-brown = 2; brown = 1), degree of soiling (very soiled = 4; somewhat soiled = 1; no soiling = 0), and consistency (very liquid
= 4; liquid = 3; solid = 1) of the stool. Bars represent the mean percentage of severity of illness score of the pups ± SEM per day.
Figure 3 Viral shedding in feces after EDIM infection. Detection of viral shedding by measuring the concentration of rotavirus (ng/ml) ± SEM in
feces after the secondary EDIM inoculation at day 17 of age. Group B was inoculated with only EDIM (A), group C was inoculated with RRV and EDIM
(B) and group D was inoculated with both RRV and EDIM and received rotavirus-specific antibodies (Gastrogard-R
®) prior and during RRV infection (C).
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® group
(group D) showed a significant increase in T cell prolif-
eration (p < 0.05 and p < 0.0001 respectively) compared
to non-infected mice. These results suggest that multiple
infections are needed to acquire a sufficient amount of
rotavirus-specific memory T cells in the spleen to be
able to re-stimulate these T cells in vitro.
Rotavirus-specific serum IgM and IgG antibodies
Rotavirus-specific IgM and IgG were measured in the
serum individually collected at day 16 and then pooled
per group (pre-EDIM serum) and in the individual sera
of the pups collected at day 28 (post-EDIM serum).
RRV inoculation at day 7 resulted in rotavirus-specific
IgM titers (Figure 6A) in the pre-serum of about 100
AU in the RRV (group A) and RRV+EDIM (group C)
groups. There was no rotavirus-specific IgM detectable
in the EDIM group (group B). Surprisingly, even though
clinical symptoms during the RRV infection were inhib-
ited by Gastrogard-R
® (group D), a low rotavirus-speci-
fic IgM level (10 AU) was measured in this group. In
the post EDIM inoculation sera, the rotavirus-specific
IgM titers of the RRV and RRV+EDIM groups were not
different from the pre-serum, but the rotavirus-specific
IgM antibody titer was increased in the EDIM group as
well as the Gastrogard-R
® group to 90 AU.
T h er o t a v i r u s - s p e c i f i cI g Gt i t e r s( F i g u r e6 B )i nt h e
pre-serum showed similar results as the rotavirus-speci-
fic IgM with titers of about 100 AU in the RRV and
RRV+EDIM groups, non-detectable in the EDIM group
and low but detectable (20 AU) in the Gastrogard-R
®
group. Inoculation with EDIM increased the titers of
rotavirus-specific IgG in all groups (RRV 350 AU; RRV
+EDIM 520 AU; EDIM 50 AU; Gastrogard-R
® 125 AU).
Rotavirus-specific serum IgG subclass antibodies
The rotavirus-specific IgG subclasses IgG1, IgG2a, IgG2b
and IgG3 were measured in the pool serum, individually
collected and then pooled per group, at day 16 (pre-EDIM
serum) and in the individual sera of the pups collected at
day 28 (post-EDIM serum). Like rotavirus-specific IgG
titers, the pre-serum showed detectable levels of all sub-
classes in the RRV and RRV+EDIM groups, 2 times lower
in the Gastrogard-R
® group and non-detectable in the
EDIM group (data not shown). The rotavirus-specific IgG
subclass titers in the post-serum were markedly higher
and in Figure 7 the geometric mean titers (GMT) per
group are shown. Primary rotavirus inoculation at day 7 of
age (RRV; group A) showed the following antibody titers;
IgG2a antibodies (GMT 838 AU), IgG3 (GMT 213 AU),
IgG2b (GMT 164 AU) and IgG1 (GMT 131 AU). A sec-
ondary EDIM inoculation at day 17 of age (RRV+EDIM;
g r o u pC )s h o w e ds i m i l a rI g G 2 a( G M T9 8 1A U ) ,I G 2 b
(GMT 151 AU) and IgG1 (GMT 125 AU) levels, only the
amount of IgG3 seemed to be elevated (GMT 555 AU)
but this increase was not significant. Primary inoculation
with EDIM at day 17 of age (group B) resulted in low anti-
body levels for all subclasses (range 1-4 AU). Antibody
levels in the mice receiving Gastrogard-R
® were signifi-
cantly lower than the RRV+EDIM group (IgG1 p = 0.035,
IgG2a p = 0.024, IgG2b p = 0.025, IgG3 p = 0.001). How-
ever, this Gastrogard-R
® group showed significantly higher
levels of antibodies than the EDIM group (IgG1 p = 0.028,
IgG2a p = 0.002, IgG2b p = 0.002, IgG3 p = 0.007). These
results indicate that although Gastrogard-R
® had comple-
tely inhibited rotavirus-induced diarrhea during a primary
Figure 4 DTH responses to rotavirus. DTH response to EDIM by
measuring ear thickness 24 hours after administration of EDIM in
the left ear pinnea. Bars represent the mean ear swelling (10
-3 mm)
per group ± SEM. EDIM induced a significant (p = 0.01) increase in
ear swelling in the EDIM group compared to the control. The RRV,
RRV + EDIM and Gastrogard-R
® groups were not significantly
different from the control.
Figure 5 T-cell proliferation by antigen-specific stimulation
with rotavirus RRV. Spleen cells of individual mice were isolated at
day 28 and 1 × 10
6 cells were stimulated with 5 × 10
7 CCID50 UV-
inactivated RRV for 5 days. Proliferation of T cells was determined by
measuring incorporation of tritium-thymidine. Bars represents the
stimulation index (RRV stimulated cells/non-stimulated cells) ± SEM
per group. The RRV + EDIM group as well as the Gastrogard-R
®
group showed a significant increase in T cell proliferation (p < 0.05
and p < 0.0001 respectively) compared to non-infected mice
(control).
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the immune system because B cells were activated and
rotavirus-specific IgG (subclass) antibodies were produced.
Discussion
In this study a neonatal mouse model, originally devel-
oped by VanCott et al. [12], was modified to investigate
the effect of nutritional intervention (Gastrogard-R
®)
during a primary (heterologous) rotavirus infection and/
or on a secondary (homologous) rotavirus infection.
Gastrogard-R
® is prepared from the colostrum of hyper-
immunised cows and contains high antibody titers
against four human rotavirus serotypes. In parallel, the
neonatal mouse model could provide better insight into
the immunological response to rotavirus since mechan-
ism of rotavirus protection and rotavirus clearance in
mice are still not fully understood. The ability of a neo-
natal mouse or human to generate sufficient immune
effectors needed for protection after gastrointestinal
virus infection is dependent on its state of immunologi-
cal maturity. Specific immune cell functions as well as
the gastrointestinal tract mature in neonatal mice
through the weaning period, while the numbers of
immune cells in inductive and effector sites increase
gradually [14]. Many studies have been performed to
clarify the immune response to rotavirus infection.
Clearance of rotavirus can occur T cell independent
[15,16] as well as B cell/antibody independent [17,18].
Figure 6 Rotavirus-specific IgM and IgG antibody titers in serum. Rotavirus-specific IgM (A) and IgG (B) antibody titers in arbitrary units (AU)
± SD in serum collected at day 16 (pre-EDIM serum) and at day 28 (post-EDIM serum). The serum at day 16 is a pooled serum collected from all
animals within a group, at day 28 the sera were collected and tested individually (RRV n = 22; EDIM n = 23; RRV+EDIM n = 24; intervention
Gastrogard-R
® n = 22) and the mean titers are depicted.
Figure 7 Rotavirus-specific IgG-subclass antibodies in serum. Geometric mean titers (GMT) in arbitrary units (AU) ± SEM of the rotavirus-
specific IgG-subclass antibodies IgG1, IgG2a, IgG2b and IgG3 in serum individually collected at day 28, depicted per antibody.
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absolutely necessary for long-term protection against
rotavirus re-infection [7]. On the other hand, T cells are
important for antiviral immunity in mice as well. CD4
+
T cells are essential for the development of more than
90% of the rotavirus-specific intestinal IgA and their
presence seems to be critical for the establishment of
protective long term memory responses [15]. Moreover,
murine rotavirus-specific CD8
+ T cells can mediate
short-term partial protection against reinfection [19].
These data implicates that there is not one specific
route that leads to rotavirus clearance and/or protection
to rotavirus re-infection, but that both B cell as well as
T cell-dependent and independent mechanisms can lead
to clearance of infection and long-term maintenance of
protection [20]. Within the model as described herein,
both aspects of immune responses related towards pro-
tection can be studied.
Sheridan et al. was one of the first to describe a mouse
model studying rotavirus-sp e c i f i ci m m u n i t y[ 5 ] .M i c e
(CD-1) were infected orally with EDIM virus at 1, 7 or 21
days of age. Severe disease was observed in animals
infected at 1 day of age and lasted for at least 9 days. Dis-
ease was observed in mice infected at day 7 of age also,
but was less severe and lasted only 5 days. Mice infected
at 21 days of age did not show any evidence of clinical ill-
ness. These findings were comparable to our study where
t h em i c ew e r ei n o c u l a t e dw i t hR R Va td a y7o fa g ea n d
illness and diarrhea was seen for 5 days in approximately
70% of the animals. If the animals were supplemented
with rotavirus-specific antibodies (Gastrogard-R
®)o r a l l y ,
the animals were protected completely from rotavirus-
induced diarrhea. Inoculation of EDIM at day 17 of age
did not result in any clinical symptoms and infection was
measured by the analysis of rotavirus shedding in feces.
Fecal viral shedding after a secondary EDIM inoculation
showed that a primary rotavirus infection protected
against viral shedding by 81% during a secondary inocu-
lation. Administration of Gastrogard-R
®, which comple-
tely protected the mice from diarrhea and illness during
a primary infection, showed no protection during the sec-
ondary inoculation though the viral shedding seemed to
disappear more rapidly compared to the group which
received only EDIM without primary RRV inoculation.
Delayed-type hypersensitivity (DTH) is an important
in vivo manifestation of cell-mediated immune responses.
In our study, a rotavirus-specific DTH using EDIM was
elicited at day 27 of age. In mice only inoculated with RRV
at day 7, no DTH response was measurable compared to
the control group. The mice receiving only EDIM at the
age of 17 days however showed a significant DTH
response to EDIM. This DTH disappeared in the mice
which have been inoculated with both RRV and EDIM.
Thus, not only adult mice that were re-infected after a
primary infection showed a suppressed DTH as seen pre-
v i o u s l yb yS h e r i d a ne ta l[ 5 ]b u ta l s om i c ew h or e c e i v e d
the primary infection at a young age and a re-infection
at an older age showed the same DTH suppression. Cellu-
lar responses to rotavirus were also analyzed by ex vivo
restimulation of T cells isolated from the spleen with UV-
inactivated rotavirus. Inactivation by exposure to UV
radiation destroys the integrity of rotavirus RNA and also
removes the non-specific stimulatory effects of the virus
when assayed on non-immune cells. A disadvantage of
UV-inactivation over live virus is that inactivated virus has
been shown to produce a lower level of proliferation than
that induced by live virus [21]. In the present experiments,
the proliferation level was low, although a significant
increase in T cell proliferation was seen in the mice receiv-
ing both RRV and EDIM and also in the Gastrogard-R
®
group. In these mice, even though during a primary infec-
tion clinical illness was completely blocked, the immune
system was activated.
>Much controversy still exists as to whether serum
antibodies against rotavirus are directly involved in pro-
tection or merely reflect recent infection, leaving the
protective role to mucosal or cell-mediated immunity.
Reviewed data from a variety of studies in humans sug-
gest that serum antibodies, if present at critical levels,
are either protective themselves or are an important and
powerful correlate of protection against rotavirus disease
[22]. Previous studies in infant mice, rabbits and
humans have determined that rotavirus-specific IgM
levels increase during the acute-phase of infection
(before 7 days p.i.) and then decrease gradually. There-
fore, rotavirus-specific IgM is seen as a marker of pri-
mary infection. Rotavirus-specific IgA and IgG levels
were increased in the convalescent-phase of the infec-
tion [5,23,24]. Administration of RRV at day 7 resulted
in the development of an antibody titer after 21 days,
predominantly of the IgG2a subclass. Similar subclass
restriction after virus infections was seen previously
[25,26]. Administration of EDIM to previously RRV
inoculated mice did not result in an increase of the anti-
body titer. Administration of EDIM at day 17 without a
previous RRV inoculation resulted in normal levels of
rotavirus-specific IgM and a small amount of rotavirus-
specific IgG (subclass) antibodies, most likely due to the
fact that 10 days p.i. is too early to measure the develop-
ment of IgG antibodies. Intervention with Gastrogard-
R
® showed low antibody titers, but still significantly
higher than the group who were inoculated with EDIM
only, indicating that the rotavirus, although not able to
induce diarrhea during the primary infection, could still
provoke an antibody reaction.
Gastrogard-R
® is prepared from colostrum of hyper-
immunised cows and contains high antibody titers
against four human rotavirus serotypes, as measured in
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immunization was established in calves which were
immunized by subcutaneous injection of colostral whey
with a high IgGl rotavirus antibody titer and challenged
with virulent bovine rotavirus 48 h later. Calves were
protected from rotavirus infection and diarrhea. Results
further indicated that circulating IgG1 antibody
appeared in the gastrointestinal tract of neonatal calves
[27]. Previous research already showed that rotavirus
antibody activity survived passage through the human
gastrointestinal tract [28]. Gastrogard-R
® is used as pro-
phylactic treatment of ‘at risk’ children aged one month
to three years to prevent diarrhea due to rotavirus infec-
tion. The efficacy of treatment with Gastrogard-R
® was
established in a clinical trial in children aged 3 to 15
months [13]. The in vitro inhibitory effect of Gastro-
gard-R
® was established in our laboratory in a rotavirus
(RRV) titration assay using MA-104 cells (data not
shown). In this assay Gastrogard-R
® was shown to have
a strong inhibitory effect on the infectivity of rotavirus
with an IC50 of 1 μg/ml. Bovine milk and bovine milk
constituents like lactadherin have been studied on their
inhibitory activity in vitro and in in vivo rotavirus mod-
els [29]. Various compounds present in whey protein
concentrate can ameliorate the severity and incidence of
experimental rotaviral diarrhea and modulate the muco-
sal and systemic immune in suckling rats [30] and suck-
ling mice [31]. However, none of these dairy
compounds were able to completely inhibit clinical
symptoms during a primary rotavirus infection, which is
usually attended with the most severe clinical symptoms
like diarrhea and vomiting [32].
Conclusions
In this study was found that oral administration of rota-
virus antibodies can completely protect neonatal mice
from clinical symptoms of illness during a primary rota-
virus infection. Furthermore, an enhanced rotavirus-speci-
fic T cell proliferation and a small but detectable level of
rotavirus-specific antibodies were found after re-infection
suggesting improved T cell responses and a slight B cell
response. Also shedding of rotavirus after EDIM inocula-
tion seemed to disappear more rapidly in mice treated
with rotavirus antibodies than in mice inoculated with
EDIM alone. These results indicate that even though
symptoms of a primary rotavirus infection were prevented,
an activation of the immune system was still detectable.
Preventing a primary infection by using Gastrogard-R
®,
activation of the immune system can still occur and could
be helpful during re-infection knowing that both arms of
the immune system play a pivotal role in immunity to
rotavirus infection. These data show that this intervention
model can be used for studying clinical symptoms as well
as immune responses required for protection against viral
re-infection.
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